Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3067 - Treatment-Free Interval (TFI) Following Discontinuation of First-Line Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Patients (Pts) With Advanced Renal Cell Carcinoma (aRCC): CheckMate 214 Analysis

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

David McDermott

Citation

Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283

Authors

D.F. McDermott1, B.I. Rini2, R.J. Motzer3, N.M. Tannir4, B. Escudier5, C.K. Kollmannsberger6, H.J. Hammers7, C. Porta8, S. George9, F. Donskov10, H.P. Gurney11, M. Grimm12, M. Harrison13, T.E. Hutson14, J. Doan15, S. Yang15, S. Rao15, S. Mekan16, A. Ambavane17, T. Powles18

Author affiliations

  • 1 Department Of Medicine, Beth Israel Deaconess Medical Center, Dana–Farber/Harvard Cancer Center, 2215 - Boston/US
  • 2 Department Of Hematology And Oncology, Cleveland Clinic Taussig Cancer Institute, 44195 - Cleveland/US
  • 3 Department Of Medicine, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 4 Department Of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 77030-3721 - Houston/US
  • 5 Department Of Medical Oncology, Gustave Roussy, 94805 - Villejuif/FR
  • 6 Division Of Medical Oncology, British Columbia Cancer Agency, V5Z 4E6 - Vancouver/CA
  • 7 Division Of Hematology And Oncology, UT Southwestern – Kidney Cancer Program, 75390-8576 - Dallas/US
  • 8 Department Of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, 27100 - Pavia/IT
  • 9 Department Of Medicine, Roswell Park Cancer Institute, 14263 - Buffalo/US
  • 10 Department Of Oncology, Aarhus University Hospital, 8000 - Aarhus/DK
  • 11 Department Of Medical Oncology, Westmead Hospital and Macquarie University, 2145 - Westmead/AU
  • 12 Department Of Urology, Jena University Hospital, 7740 - Jena/DE
  • 13 Department Of Medicine, Duke University Medical Center, 27710 - Durham/US
  • 14 Department Of Medicine, Texas A&M HSC College of Medicine, 75246 - Dallas/US
  • 15 Health Economics And Outcomes Research, Bristol-Myers Squibb, 08540 - Princeton/US
  • 16 Health Economics And Outcomes Research, Bristol-Myers Squibb, NJ 08648 - Lawrenceville/US
  • 17 Modeling And Simulation, Evidera Inc, W6 8DL - London/GB
  • 18 Department Of Medicine, Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, EC1M 6BQ - London/GB
More

Resources

Abstract 3067

Background

Pts with metastatic melanoma who discontinue N+I may experience sustained clinical benefit and a delayed need for subsequent therapy. In this analysis, TFI was retrospectively analyzed using data from the phase 3 CheckMate 214 trial, in which N+I demonstrated superior efficacy vs S in pts with IMDC intermediate/poor (int/poor)-risk aRCC.

Methods

In CheckMate 214, pts with previously untreated clear cell aRCC were randomized 1:1 to N 3 mg/kg + I 1 mg/kg every 3 weeks for 4 doses followed by N 3 mg/kg every 2 weeks, or S 50 mg daily orally for 4 weeks (6-week cycles). TFI was defined as the time from last dose of N+I or S to the start of subsequent systemic therapy or death. All randomized pts with IMDC int/poor-risk aRCC (N+I, 425; S, 422) were analyzed. Kaplan–Meier curves and log-rank tests were used to compare TFI between N+I and S.

Results

With median overall survival follow-up of 25.2 months, pts in the N+I arm had significantly longer time from randomization to subsequent systemic therapy or death than pts in the S arm (median, 15.4 vs 8.5 months; P < 0.0001); 2 years after randomization, 42% vs 19% of pts were alive and not requiring subsequent therapy. Overall, 320 (75%) N+I pts and 359 (85%) S pts discontinued treatment, most commonly due to disease progression (N+I, 42%; S, 58%) or study drug–related adverse events (N+I, 23%; S, 11%). In pts who discontinued, TFI was significantly longer with N+I than with S (P < 0.0001); 18 months after discontinuation, 19% of N+I pts vs 4% of S pts remained treatment-free. TFI was also significantly longer with N+I than with S, irrespective of best overall response on study (P < 0.0001). 18 months after discontinuation, 48% of N+I pts vs 6% of S pts with complete/partial response were still free of subsequent treatment; at the same time point, 13% of N+I pts vs 4% of S pts with stable disease remained treatment-free.

Conclusions

The use of N+I was associated with a significant longer TFI beyond treatment discontinuation in pts with IMDC int/poor-risk aRCC and irrespective of whether pts achieved response or disease control. TFI should be considered along with traditional efficacy measures when evaluating treatment options for aRCC.

Clinical trial identification

NCT02231749.

Legal entity responsible for the study

Bristol-Myers Squibb.

Funding

Bristol-Myers Squibb and ONO Pharmaceutical Company Limited.

Editorial Acknowledgement

Professional medical writing and editorial assistance were provided by Richard Daniel, PhD, and Lawrence Hargett of PPSI (a PAREXEL company), funded by Bristol-Myers Squibb.

Disclosure

D.F. McDermott: Consulting or advisory role: Array BioPharma, Bristol- Myers Squibb, Eisai, Exelixis, Genentech, Merck, Novartis, Pfizer; Research funding: Prometheus (Inst). B.I. Rini: Consulting or advisory role: Bristol-Myers Squibb. R.J. Motzer: Consulting or advisory role: Eisai, Exelixis, Genentech/Roche, Merck, Novartis, Pfizer; Research funding: Bristol-Myers Squibb, Eisai, Exelixis, Novartis, Pfizer. N.M. Tannir: Research funding: Bristol-Myers Squibb, Epizyme, Exelixis, Mirati, Novartis; Consulting or advisory role: Argos, Bristol-Myers Squibb, Eisai, Exelixis, Nektar, Novartis, Oncorena, Pfizer; Advisory board member: Eisai, Exelixis, Nektar, Novartis, Oncorena. B. Escudier: Honoraria: Bristol-Myers Squibb, Bayer, Novartis, Pfizer, Exelixis, Roche. C.K. Kollmannsberger: Honoraria: Bristol-Myers Squibb, Pfizer; Consulting or advisory role: Bristol-Myers Squibb, Pfizer. H.J. Hammers: Consulting or advisory role: Bristol-Myers Squibb, Pfizer, Exelixis; Research funding: Bristol-Myers Squibb; Travel, accommodations, expenses: Bristol Myers Squibb, Pfizer, Exelixis. C. Porta: Consulting or advisory role: Bristol-Myers Squibb, Pfizer, Novartis, Ipsen, Eisai, EUSA, Janssen. S. George: Consulting or advisory role: Bristol-Myers Squibb, Novartis, Bayer, Pfizer, Exelixis, AstraZeneca, Janssen Oncology, Corvus Pharmaceuticals, Genentech/Roche; Research funding to institution: Pfizer, Acceleron Pharma, Merck, Agensys, Novartis, Bristol-Myers Squibb, Bayer. F. Donskov: Research funding to institution: Ipsen, Novartis, Pfizer. H.P. Gurney: Consulting or Advisory Role: Astellas, Bristol-Myers Squibb, Novartis, Pfizer. M-O. Grimm: Honoraria: Pfizer, MSD, Apogepha; Consulting or advisory role: Roche; Research funding: Novartis, Bristol-Myers Squibb. T.E. Hutson: Speaker, research support and advisor: Bristol-Myers Squibb, Pfizer, Novartis, Aveo, Exelexis, Janssen. J. Doan, S. Yang, S. Rao, S. Mekan: Employment, Stock or other ownership: Bristol-Myers Squibb. A. Ambavane: Employment: Evidera, Inc. which received fees for consulting support from Bristol-Myers Squibb and EMD Serono. T. Powles: Research funding: AstraZeneca, Novartis, Roche Honoraria: AstraZeneca, Merck, Bristol-Myers Squibb, Pfizer, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings